Company intelligence
NewCelX
Biotechnology company advancing transformative therapies for neurodegenerative and metabolic diseases
About NewCelX
NewCelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company’s integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. NewCelX is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel.
Verified activity
Signals from NewCelX
3 published signals
Products & Services
NewCelX is advancing NCEL-101 using a proprietary differentiation and enrichment platform designed to produce highly purified, functional insulin-producing islet cells.
Reported by NewCelX
Research & Knowledge
NewCelX and NCEL-101 preclinical stem cell-derived islet cell therapy was highlighted by the Breakthrough T1D Center of Excellence at UMass Chan Medical School as a critical requirement for type 1 diabetes cell therapy.
Reported by NewCelX
Research & Knowledge
NewCelX is developing NCEL-101, an enriched stem cell-derived islet cell therapy designed to restore functional insulin production through scalable, off-the-shelf cell replacement.
Reported by NewCelX